Total Valuation
Egetis Therapeutics AB has a market cap or net worth of €325.77M. The enterprise value is $2.34K.
Market Cap€325.77M
Enterprise Value$2.34K
Share Statistics
Egetis Therapeutics AB has 464,947,240 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding464,947,240
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Egetis Therapeutics AB’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -79.16%.
Return on Equity (ROE)-1.01
Return on Assets (ROA)-0.54
Return on Invested Capital (ROIC)-79.16%
Return on Capital Employed (ROCE)-0.87
Revenue Per Employee1.11M
Profits Per Employee-6.12M
Employee Count56
Asset Turnover0.10
Inventory Turnover21.74
Valuation Ratios
The current PE Ratio of Egetis Therapeutics AB is ―. Egetis Therapeutics AB’s PEG ratio is 0.34.
PE Ratio―
PS Ratio31.51
PB Ratio5.81
Price to Fair Value5.81
Price to FCF-7.32
Price to Operating Cash Flow-11.79
PEG Ratio0.34
Income Statement
In the last 12 months, Egetis Therapeutics AB had revenue of 62.40M and earned -342.50M in profits. Earnings per share was -0.93.
Revenue62.40M
Gross Profit12.40M
Operating Income-346.90M
Pretax Income-342.10M
Net Income-342.50M
EBITDA-343.20M
Earnings Per Share (EPS)-0.93
Cash Flow
In the last 12 months, operating cash flow was -300.30M and capital expenditures -1.00M, giving a free cash flow of -301.30M billion.
Operating Cash Flow-300.30M
Free Cash Flow-301.30M
Free Cash Flow per Share-0.65
Dividends & Yields
Egetis Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.66
52-Week Price Change55.91%
50-Day Moving Average0.60
200-Day Moving Average0.50
Relative Strength Index (RSI)59.60
Average Volume (3m)128.00
Important Dates
Egetis Therapeutics AB upcoming earnings date is Nov 6, 2026, TBA (Confirmed).
Last Earnings DateAug 21, 2026
Next Earnings DateNov 6, 2026
Ex-Dividend Date―
Financial Position
Egetis Therapeutics AB as a current ratio of 1.05, with Debt / Equity ratio of 14.29%
Current Ratio1.05
Quick Ratio1.04
Debt to Market Cap0.04
Net Debt to EBITDA0.36
Interest Coverage Ratio-15.28
Taxes
In the past 12 months, Egetis Therapeutics AB has paid 400.00K in taxes.
Income Tax400.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Egetis Therapeutics AB EV to EBITDA ratio is -5.36, with an EV/FCF ratio of -6.85.
EV to Sales29.50
EV to EBITDA-5.36
EV to Free Cash Flow-6.85
EV to Operating Cash Flow-6.89
Balance Sheet
Egetis Therapeutics AB has €378.40M in cash and marketable securities with €68.80M in debt, giving a net cash position of €309.60M billion.
Cash & Marketable Securities€378.40M
Total Debt€68.80M
Net Cash€309.60M
Net Cash Per Share€0.67
Tangible Book Value Per Share-€0.09
Margins
Gross margin is 16.79%, with operating margin of -555.93%, and net profit margin of -548.88%.
Gross Margin16.79%
Operating Margin-555.93%
Pretax Margin-548.24%
Net Profit Margin-548.88%
EBITDA Margin-550.00%
EBIT Margin-555.93%
Analyst Forecast
The average price target for Egetis Therapeutics AB is €2.07, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€2.07
Price Target Upside― Downside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast43.57%
EPS Growth Forecast-4.85%